The Use of Real-World Data and Real-World Evidence in Decisions about Biosimilars and Interchangeable Biologics
Tuesday, November 8, 2022
3:00 p.m. - 4:00 p.m.
What role can real-world data and real-world evidence play in making decisions about biosimilars and interchangeable biologics? How can this data be used to help prescribing clinicians and other decision-makers make decisions regarding biosimilar-to-biosimilar cross-switching? This session will explore these questions and the barriers that stand in the way of using real-world data and real-world evidence to help increase the market uptake of biosimilars and interchangeable biologics.
Moderator: Monét Stanford, PharmD
Director, Policy, AAM
Efe Eworuke, PhD
Associate Director for Science, Division of Epidemiology, Office of Surveillance and Epidemiology, CDER, FDA
Joe Franklin, JD, PhD
Head of Strategic Affairs, CSP, Verily
Michael Kleinrock, M.A.
Senior Research Director, IQVIA Institute for Human Data Science
Cate Lockhart, PharmD, PhD
Executive Director, Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)
